Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).

OBJECTIVE We investigated patient and disease characteristics predictive of relapse of MDD during a 52-week placebo controlled trial of selegiline transdermal system (STS) to identify patient characteristics relevant for STS treatment. METHOD After 10 weeks of open-label stabilization with STS, 322 remitted patients with MDD were randomized to 52-weeks of… CONTINUE READING